NUVB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nuvation Bio Inc. (NUVB) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company shows promise with its Ibtrozi launch and strong revenue growth, the negative net income trend, lack of significant trading signals, and ongoing legal investigations create uncertainty. It is better to wait for more clarity on these issues before investing.
The MACD is positive and expanding (0.0906), indicating bullish momentum. RSI at 67 is neutral, and moving averages are converging, suggesting no clear trend. The pre-market price of $4.66 is near the first resistance level (R1: 4.719), indicating limited immediate upside.
The Ibtrozi drug launch shows strong uptake and potential for significant revenue growth. Analysts have raised price targets, with RBC Capital and Truist highlighting long-term upside potential.
Ongoing legal investigations into potential breaches of fiduciary duties by executives create uncertainty. Net income and EPS are declining, and there is no recent congress trading data to indicate confidence from influential figures.
In Q4 2025, revenue increased by 633.06% YoY to $41.87M, and gross margin improved to 96.94%. However, net income dropped by 25.99% YoY to -$36.59M, and EPS declined by 26.67% to -$0.11.
Analysts are mixed. UBS lowered its price target to $7 with a Neutral rating, while RBC Capital and Truist raised their targets to $13, maintaining Outperform and Buy ratings, respectively. Analysts highlight the strong potential of the Ibtrozi franchise.
